StreetInsider.com News Articles

Radiopharm reports partial response in RAD204 cancer drug trial

Wed, 22 Jul 2026 07:05:14 -0400

Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) reported updated clinical results from the third dosing cohort of its Phase 1 trial of RAD204, a PD-L1-targeted lutetium-177 radiotherapeutic being evaluated in patients with advanced solid tumors following prior immunotherapy.

According to the company, the first patient in cohort three achieved a RECIST-confirmed partial response after the second treatment cycle, with tumor reductions of 19% after dose one, 43% after dose two, 43% after dose three, and 35% after dose four. The patient has remained progression-free beyond seven months across four treatment cycles.

A second patient in the cohort showed a 7% reduction in target

Radiopharm reports partial response in RAD204 cancer drug trial

Wed, 22 Jul 2026 07:05:14 -0400

A second patient in the cohort showed a 7% reduction in target

Radiopharm reports partial response in RAD204 cancer drug trial

Wed, 22 Jul 2026 07:05:14 -0400

A second patient in the cohort showed a 7% reduction in target

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Wed, 22 Jul 2026 07:05:00 -0400

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment

RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far

SYDNEY and MALVERN, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need,

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Wed, 22 Jul 2026 07:05:00 -0400

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment

RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Wed, 22 Jul 2026 07:05:00 -0400

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment

RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Wed, 22 Jul 2026 07:05:00 -0400

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment

RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Wed, 22 Jul 2026 07:05:00 -0400

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment

RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Wed, 22 Jul 2026 07:05:00 -0400

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment

RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far

Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

Wed, 22 Jul 2026 07:00:38 -0400

Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) reported that its RAD101 imaging agent met the primary endpoint of a Phase 2b clinical trial, showing 93% concordance between PET and MRI imaging across all evaluable lesions in patients with suspected recurrent brain metastases.

The U.S. multicenter, open-label, single-arm trial enrolled 30 evaluable patients with suspected recurrence of brain metastases from solid tumors following stereotactic radiosurgery. Among 14 patients with available six-month follow-up and biopsy data, preliminary sensitivity — the ability to correctly identify patients with disease — was 86%. Specificity data is expected in the fourth quarter of 2026.

RAD101 is a small molecule

Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

Wed, 22 Jul 2026 07:00:38 -0400

RAD101 is a small molecule

Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

Wed, 22 Jul 2026 07:00:38 -0400

RAD101 is a small molecule

Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

Wed, 22 Jul 2026 07:00:38 -0400

RAD101 is a small molecule

Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

Wed, 22 Jul 2026 07:00:38 -0400

RAD101 is a small molecule

Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

Wed, 22 Jul 2026 07:00:38 -0400

RAD101 is a small molecule

Radiopharm RAD101 meets Phase 2b endpoint for brain metastases

Wed, 22 Jul 2026 07:00:38 -0400

RAD101 is a small molecule

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Wed, 22 Jul 2026 07:00:00 -0400

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026.

The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026

The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product

SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a